Eyevance Pharmaceuticals has announced the US launch of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the company’s acquisition of the product in late 2019. Tobradex ST is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Tobradex ST, which is the next generation of Tobradex, includes a suspension technology (ST) formulated with pharmaceutical grade xanthan gum, an inactive ingredient designed to stabilize the combination and allow greater delivery and ocular surface retention of tobramycin and dexamethasone to the eye, according to a company news release.
Eyevance has branded this ST delivery technology, now known as XanGen.
As part of its national launch of Tobradex ST, Eyevance is investing resources to launch a full-scale campaign to educate eye care professionals on the product’s strong clinical profile. Tobradex ST’s novel formulation with XanGen is designed to enhance bactericidal activity, ocular surface retention time, and enhanced bioavailability allowing for a lower concentration of dexamethasone and little-to-no blurriness or IOP spikes.
“I am very excited for Eyevance to launch Tobradex ST,” Paul M. Karpecki, OD, FAAO, Director, Cornea, Kentucky Eye Institute, said in the news release. “Ocular surface inflammation with bacterial comorbidity is often hard to treat quickly and effectively, representing a significant pain point for patients and doctors. Tobradex ST’s exceptional clinical profile makes it a highly attractive treatment option for all forms of blepharitis, conjunctivitis and contact lens acute red eye, and I have no doubt the Eyevance team will be successful in educating my colleagues on its merits.”
“We are introducing Tobradex ST to eye care professionals because it holds immense potential for millions of patients suffering from acute blepharitis, meibomian gland dysfunction, and other relevant ocular surface conditions,” Jerry St. Peter, Chief Executive Officer, Director and Co-founder, Eyevance Pharmaceuticals, said in the news release. “By ensuring optimal, consistent delivery of tobramycin and dexamethasone in every drop, Tobradex ST is designed to help patients find safe, rapid relief and return to healthy living. Our commercial team is fully trained, proud and thrilled to launch Tobradex ST.”
For complete product information about Tobradex ST, including important safety information, visit https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050818lbl.pdf.